2.50
Hdl Handle:
http://hdl.handle.net/10541/96020
Title:
Aggressive vs nonaggressive therapy for metastatic NSCLC.
Authors:
Thatcher, Nick; Niven, Robert McL; Anderson, Heather
Abstract:
Clinicians tend to underestimate potential modest benefits of chemotherapy. They are often reluctant to refer patients for chemotherapy, perhaps because they expect the side effects to outweigh any perceived benefits. However, patients are much more ready to accept chemotherapy, even when the likely benefits are small. Quality of life, change in performance status, and relief of tumor-related symptoms are important additional parameters of treatment assessment. Taking account of these other factors will help clinicians balance quality and quantity of life in patients with metastatic non-small cell lung cancer.
Affiliation:
Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.
Citation:
Aggressive vs nonaggressive therapy for metastatic NSCLC. 1996, 109 (5 Suppl):87S-92S Chest
Journal:
Chest
Issue Date:
May-1996
URI:
http://hdl.handle.net/10541/96020
PubMed ID:
8635395
Type:
Article
Language:
en
ISSN:
0012-3692
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorNiven, Robert McLen
dc.contributor.authorAnderson, Heatheren
dc.date.accessioned2010-04-08T14:35:45Z-
dc.date.available2010-04-08T14:35:45Z-
dc.date.issued1996-05-
dc.identifier.citationAggressive vs nonaggressive therapy for metastatic NSCLC. 1996, 109 (5 Suppl):87S-92S Chesten
dc.identifier.issn0012-3692-
dc.identifier.pmid8635395-
dc.identifier.urihttp://hdl.handle.net/10541/96020-
dc.description.abstractClinicians tend to underestimate potential modest benefits of chemotherapy. They are often reluctant to refer patients for chemotherapy, perhaps because they expect the side effects to outweigh any perceived benefits. However, patients are much more ready to accept chemotherapy, even when the likely benefits are small. Quality of life, change in performance status, and relief of tumor-related symptoms are important additional parameters of treatment assessment. Taking account of these other factors will help clinicians balance quality and quantity of life in patients with metastatic non-small cell lung cancer.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshHealth Status-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshQuality of Life-
dc.subject.meshSurvival Rate-
dc.subject.meshTreatment Outcome-
dc.titleAggressive vs nonaggressive therapy for metastatic NSCLC.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalChesten
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.